Follow us on Twitter
twitter icon@FreshPatents


Hypertension patents

      

This page is updated frequently with new Hypertension-related patent applications.

Therapeutic regimen for hypertension
The invention relates to improved methods, devices, and kits for identifying and implementing an appropriate treatment regimen for subjects suffering from hypertension.. .
Geneticure Llc


Potassium-binding agents for treating hypertension and hyperkalemia
The present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.
Relypsa, Inc.


Pharmaceutical composition comprising amlodipine and dextromethorphan
This application provides an oral pharmaceutical composition in a solid form comprising amlodipine or a pharmaceutically acceptable salt thereof, a low dose range of dextromethorphan or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. The composition is useful for treating hypertension..
Handa Pharmaceuticals, Inc.


5-ht2c receptor agonists and compositions and methods of use
Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
Arena Pharmaceuticals, Inc.


G protein-coupled receptor kinase inhibitors and methods for use of the same
Disclosed herein are novel grk inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of formula (i) and pharmaceutically acceptable salt thereof, wherein the substituents are as described..
The Regents Of The University Of Michigan


Cardiac health monitoring systems and methods involving hypertension relief device(s) and/or features
Systems and methods involving hypertension monitoring and/or treatment device(s) are disclosed. According to implementations herein, various combination systems, devices and methods that provide therapy and/or monitoring capabilities of a person's blood pressure, incorporating a ppg/ecg integrated sensor within the handle of a hypothermia therapy device for persons with hypertension, are provided..
Physiocue, Inc.


Drug therapy for preventing or treating glaucoma
There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma..
Kowa Co., Ltd.


Use of fk506 for the treatment of pulmonary arterial hypertension
A method for reducing pulmonary hypertension in a mammal that employs fk506 is provided. In certain embodiments, the method comprises administering fk506 to a mammal having pulmonary arterial hypertension associated with defective mbpr2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal..
The Board Of Trustees Of The Leland Stanford Junior University


Compositions and methods for diagnosis and treatment of inflammation
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.. .
The United States Of America As Represented By The Secretary Of The Navy


Methods of treating metabolic syndrome using dopamine receptor agonists
The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from metabolic syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier..
Veroscience, Llc


Intravenous fluid

Disclosed are intravenous hypertonic electrolyte solutions for treating intracranial hypertension while reducing the risk of inducing hyperchloremic metabolic acidosis. The solutions are characterized by a ratio of sodium-to-chloride (na:cl) ions of 1.2-1.6 and a total osmolarity of 310-400 meq/l for a maintenance solution, and a total osmolarity greater than 1000 meq/l for an initiation solution..

Biomarkers for nanoparticle compositions

The present invention provides methods and compositions for treating a hyperplasia (such as cancer, restenosis, or pulmonary hypertension) by administering a composition comprising nanoparticles that comprise an mtor inhibitor (such as a limus drug) and an albumin based upon the status of an mtor-activating aberration.. .
Abraxis Bioscience, Llc

Compositions for use in treating pulmonary arterial hypertension

The present disclosure provides methods of treating pulmonary arterial hypertension (pah) in a subject in need thereof. Compositions for use in these methods are also provided..
Peloton Therapeutics, Inc.

Screening and use of piperidino pyrazolopyrimidine compound

Provided is a cell line deposited under the number of cgmcc11091 and preparation method thereof. The method comprises: using a critical downstream gene of the bmp signal, the id1 gene, as a target, then designing dual reporter gene elements to insert in an id1 genome, so as to construct a recombination vector, and transcribing the same in a human embryonic stem cell line.
Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences

Bicyclic dihydropyrimidine-carboxamide derivatives as rho- kinase inhibitors

Bicyclic dihydropyrimidine-carboxamide compounds of formula i described herein inhibit rho kinase and may be useful in the treatment of many disorders associated with rock enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (copd), idiopathic pulmonary fibrosis (ipf), and pulmonary arterial hypertension (pah).. .
Chiesi Farmaceutisi S.p.a.

Treprostinil derivatives and compositions and uses thereof

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension..
Corsair Pharma, Inc.

Polynucleotide agents targeting angiotensinogen (agt) and methods of use thereof

The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting an angiotensinogen (agt) gene, and methods of using such polynucleotide agents to inhibit expression of agt and to treat subjects having an agt-associated disease, e.g., hypertension.. .
Alnylam Pharmaceuticals, Inc.

Use of a statin compound as local drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Pharmaceutical formulations comprising a pyridylaminoacetic acid compound

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent..
Santen Pharmaceutical Co., Ltd.

Treprostinil derivative compounds and methods of using same

Compounds represented by formulae i, ii, iii, and iv including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (ph) or pulmonary arterial hypertension (pah).
Corsair Pharma Inc.

Method of treating proteinuria in pregnancy

A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes.
Curemark, Llc

Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using l-ornithine phenylacetate.. .
Ocera Therapeutics, Inc.

Ocular implant with therapeutic agents and methods thereof

Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye.
Dose Medical Corporation

Therapeutic agent and therapeutic pulmonary hypertension

The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “il-5r”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of il-5r and a therapeutic method therefor..
Kyowa Hakko Kirin Co., Ltd.

Application of high-intensity focused ultrasound system to treatment of essential hypertension

An application of a high-intensity focused ultrasound system to treatment of essential hypertension. A treatment process includes: conducting ultrasonic positioning measurement on both sides of perirenal fat tissue of a patient, setting a therapeutic window and parameters of the system, and setting corresponding power parameter of the system, so as to make local temperature of the tissue during treatment reach 40-70° c., wherein treatment portions are both sides, and treatment scope is one third to all of the whole tissue; starting the system to treat one side of the tissue according to the set parameters and then the other.
Nanjing Khons Medtech Co., Ltd.

Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Pharmaceuticals compositions comprising the 2s, 4r, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2r, 4s ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, metabolic syndrome, and other diseases and conditions, including but not limited to cushing's syndrome, depression, and glaucoma.. .
Cortendo Ab (publ)

Trans10:cis12 isomer of conjugated linoleic acid as a therapeutic and preventative agent for hypertension specific to pregnancy

Described herein are compositions and methods for the use of t10:c12 conjugated linoleic acid to reduce hypertension in pregnant women. Advantageously, by reducing blood pressure, the compositions will also reduce the risk of pre-term birth.
Wisconsin Alumni Research Foundation

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

There is disclosed a method for administration of a formulation of resiniferatoxin (rtx) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (trpv1)-expressing csar (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (lvedp), lung edema, and combinations thereof, comprising administering an effective amount of rtx directly to a tissue site selected from the group consisting of epicardium, a t1-t4 dorsal root ganglion and intrathecally to the t1-t4 region of the spinal column..
Board Of Regents Of The University Of Nebraska

Multi-pole synchronous pulmonary artery radiofrequency ablation catheter

A multi-pole synchronous pulmonary artery radiofrequency ablation catheter may comprise a control handle, a catheter body and an annular ring. One end of the catheter body may be flexible, and the flexible end of the catheter body may be connected to the annular ring.
Pulnovo Medical (wuxi) Co., Ltd

Methods and systems for measuring plasma renin activity

Disclosed are methods and systems for the quantification of angi and/or determination of plasma renin activity in a sample. The methods and systems disclosed herein can be useful for diagnosis of hypertension, aldosteronism and other abnormalities of the renin angiotensin aldosterone system (raas)..
Laboratory Corporation Of America Holdings

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

Method and controlling spinal cord stimulation to treat hypertension

An example of a system for modulating blood pressure may include a blood pressure monitoring circuit, a blood pressure modulation device, and a control circuit. The blood pressure monitoring circuit may be configured to sense signals and generate one or more blood pressure parameters indicative of the blood pressure and/or a vascular resistance and one or more activity parameters indicative of an activity level and/or a postural change using the sensed signals.
Boston Scientific Neuromodulation Corporation

Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

The present invention provides a composition comprising a therapeutically effective amount of a polypeptide, peptide, or analog corresponding to one or more of seq id no(s) 1, 2, 3 or 4, and or more of a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, and/or pharmaceutically acceptable excipient. The polypeptide therapeutic of the present invention may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation.
Imagine Pharma

Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal

The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof.
Relypsa, Inc.

Compositions for the treatment of hypertension

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin ii receptor blocker, a diuretic, a calcium channel blocker, and a beta-blocker, wherein the dose of each component is below the lowest dose approved for the treatment of hypertension for the component.. .
The George Institute For Global Health

Methods and compositions for treating pulmonary hypertension

The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g., paclitaxel) or a derivative4 thereof..
Abraxis Bioscience, Llc

A predicting the risk of incidence of chronic kidney diseases

The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (ckd) using pro-enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases.
Sphingotec Gmbh

Use of aptamers in therapy and/or diagnosis of autoimmune diseases

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
Max-delbrueck-centrum Fuer Molekulare Medizin

Compositions and methods of use for (pro)renin receptor antagonists

Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (prr) antagonist. In some instances the prr antagonist is a polypeptide.
University Of Utah Research Foundation

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Methods for treating pulmonary hypertension

The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of formula 1, which is an arylpiperazine derivative..
Reviva Pharmaceuticals, Inc.

Methods and formulations for modulating lyn kinase activity and treating related disorders

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., syndrome x), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type ii diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence..
Melior Pharmaceuticals I, Inc.

Compositions and methods for the treatment or prevention of pulmonary hypertension

The present invention provides compositions and methods for the treatment or prevention of pulmonary hypertension comprising administering an ascomycin, or a pharmaceutically acceptable salt, solvate, analog, or prodrug thereof to the patient with pulmonary hypertension.. .
Vivus, Inc.

Methods and systems for treating intracranial hypertension and related indications using an optic nerve stent or shunt

Embodiments of the present specification provide surgical methods and apparatuses to deploy at least one stent through an optic nerve sheath in order to maintain an opening/fenestration for intracranial fluid egress. The surgical method creates a fenestration, an opening, a slit, or a hole, through an optic nerve sheath of a human patient.

Application of radiofrequency catheter ablation system to treatment of essential hypertension

An application of a radiofrequency catheter ablation system to treatment of essential hypertension. The treatment process is under ultrasonic guidance, an electrode needle is made to penetrate into target tissue of a patient, electrification is conducted to start ablation, the needle is withdrawn or made to penetrate into the other side of the target tissue for target ablation after reaching ablation temperature and duration time, and overall ablation treatment is completed.
Nanjing Khons Medtech Co., Ltd.

Nitric oxide donating derivatives of fluprostenol

The present invention relates to 15-nitrooxyderivatives of fluprostenol, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxy derivatives of fluprostenol.. .
Nicox S.a.

Nitric oxide donating derivatives of latanoprost free acid

The present invention relates to 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid.. .
Nicox S.a.

Combination therapy for treating pulmonary hypertension

The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a pdgf receptor kinase inhibitor, pdev inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of pah..
Pulmokine, Inc.

Oral solid dosage form of amlodipine and veterinary uses thereof

The invention relates to the field of animal health. In particular, the invention relates to an oral solid dosage form comprising, as pharmaceutically active compounds, amlodipine.
Ceva Sante Animale

Enalapril compositions

Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction..
University Of Kansas

Method of treating skin disorders

In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism.
Mymd Pharmaceuticals, Inc.

Cannabis based compositions and methods of treating hypertension

The invention relates to a cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant cannabis sativa, subspecies sativa and cannabis sativa, subspecies indica of the ctsx-iss lineage; and methods of treatment of primary and secondary hypertension, the secondary hypertension resulting from pheochromocytoma, primary hyperaldosteronism, adrenal hyperplasia, pulmonary hypertension, portal hypertension, folate deficiency hypertension, arterial hypertension or familial hypertension by administration between one and eight times per day.. .

Serca2 therapeutic compositions and methods of use

The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (aav)-serca2 composition to a subject in need thereof.. .
State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization

Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others.
Volant Holdings Gmbh

Amlodipine formulations

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and coronary artery disease (cad)..
Silvergate Pharmaceuticals, Inc.

Diagnostics for pulmonary arterial hypertension and sudden cardiac death

This invention relates to a diagnostic test measuring circulating scn5a proteins or gene transcripts in a test sample as a biomarker for pulmonary hypertension.. .
Rhode Island Hospital

Apparatus for delivering fluid to treat renal hypertension

A surgical apparatus for delivering fluid to treat renal hypertension including an elongated member having a distal tip and a plurality of openings formed in a sidewall proximal of the distal tip. A plurality of fluid delivery members are movably positioned in the elongated member, each of the fluid delivery members having a lumen and at least one opening communicating with the lumen for delivering fluid extravascularly.
Rex Medical, L.p.

Ldl quantitation and methods of use

The present invention features, in certain aspects, methods of promoting endocytosis of ldl with α1pi or peptides derived from α1pi. The present invention also provides methods for decreasing ldl levels in response to α1pi augmentation therapy.

Treprostinil derivative compounds and methods of using same

Compounds represented by formulae i, ii, iii, and iv including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (ph) or pulmonary arterial hypertension (pah).
Corsair Pharma, Inc.

Novel therapeutic treatments using centhaquin

Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans..
Midwestern University

Lisinopril formulations

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction..
Silvergate Pharmaceuticals, Inc.

Methods of ablating tissue using a catheter injection system

At the present time, physicians often treat patients with atrial fibrillation (af) using radiofrequency (rf) catheter systems to ablate conducting tissue in the wall of the left atrium of the heart around the ostium of the pulmonary veins. These systems are expensive and take time consuming to use.
Ablative Solutions, Inc.

Arterial wall compression stent

A compression stent for applying a localized high stress against a blood vessel wall to cause vessel wall compression and blockage of sympathetic and nerve signal transmission within the wall of a blood vessel. The compression stent can also sever nerves located in the vessel wall.

Isolation of pulmonary arterial endothelial cells from patients with pulmonary vascular disease and uses thereof

The present disclosure provides methods of obtaining, recovering and culturing pulmonary arterial endothelial cells from an individual patient subjected to a right heart catheterization in regard to diagnosis of pulmonary hypertension. These isolated pulmonary arterial endothelial cells from an individual patient may be utilized to generate cellular phenotyping profile for the cell population, allowing generation of a personalized pharmacotherapy regime to assist the clinician in treatment and prognosis of the disorder for an individual patient..
Allegheny-singer Research Institute

Method of treating hypertension

Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of cinitapride or derivative thereof.
Cipla Limited

Therapeutic cd47 antibodies

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to cd47 of multiple mammalian species, block the binding of sirpalpha and tsp1 to cd47, promote phagocytosis of susceptible cancer cells, and reverse tsp1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing.
Tioma Therapeutics, Inc.

Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

The present invention provides anti-gremlin-1 (grem1) antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (pah).. .
Regeneron Pharmaceuticals, Inc.

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

Enalapril formulations

Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction..
Silvergate Pharmaceuticals, Inc.

Therapeutic cd47 antibodies

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to cd47 of multiple mammalian species, block the binding of sirpalpha and tsp1 to cd47, promote phagocytosis of susceptible cancer cells, and reverse tsp1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing.
Tioma Therapeutics, Inc.

N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives

The invention provides certain n-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition.
Cardioxyl Pharmaceuticals, Inc.

Compositions and methods for treating pulmonary hypertension

In some aspects, the disclosure relates to gdf/bmp antagonists and methods of using gdf/bmp antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (ph), particularly treating, preventing or reducing the progression rate and/or severity of one or more ph-associated complications. The disclosure also provides methods of using a gdf/bmp antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy.
Acceleron Pharma Inc.

Ifetroban treatment of portal hypertension

The present invention is directed to methods of treating and/or ameliorating portal hypertension by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.. .
Cumberland Pharmaceuticals, Inc.

Vascular calcification prevention and treatment

The invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (vsmcs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (vc) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.
Summit Innovation Labs Llc

Metabolic syndrome treatment

Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc

Methods of treating cancers, autoimmune disorders, and other conditions associated with chronic inflammation

In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism.
Mymd Pharmaceuticals, Inc.

Systems and methods for treating pulmonary hypertension

A system for treating heart disease, such as pulmonary hypertension or right heart failure, including an implantable component and external components for monitoring the implantable component is provided. The implantable component may include a compliant member, e.g., balloon, coupled to a reservoir via a conduit.
Aria Cv, Inc.

Pain relief salt composition and method

A pain relief salt composition. An embodiment of the composition includes a blend of proprietary essential oils mixed with epsom salt and dead sea salt.

Pharmaceutical for prophylaxis or treatment of hypertension

A pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension. The pharmaceutical is characterized by comprising (i) a specific mineralocorticoid receptor antagonist and (ii) one or more components selected from the following components (a) to (c), for administration simultaneously or separately at a time interval: (a) an angiotensin ii receptor antagonist, (b) a calcium antagonist, and (c) a diuretic..
Daiichi Sankyo Company, Limited

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases..
University Of Southern California

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

Vagus nerve and carotid baroreceptor stimulation system

Systems and methods are provided for delivering vagus nerve stimulation and carotid baroreceptor stimulation to patients for treating chronic heart failure and hypertension. The vagus nerve stimulation and carotid baroreceptor stimulation therapies may be provided using a single implantable pulse generator, which can coordinate delivery of the therapies..
Cyberonics, Inc.

Liquid formulation

The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.. .
Luoda Pharma Pty Ltd

Methods and systems for treating hypertension using an implantable electroacupuncture device

An electroacupuncture device for treating hypertension in a patient includes 1) a housing configured to be implanted beneath a skin surface of the patient at an acupoint corresponding to a target tissue location within the patient, the acupoint comprising at least one of pc5, pc6, st36, and st37, 2) a central electrode of a first polarity and centrally located and substantially planar on a first surface of the housing, 3) an annular electrode of a second polarity and that surrounds the central electrode on the first surface of the housing, the annular electrode being spaced apart from the central electrode, and 4) pulse generation circuitry located within the housing and electrically coupled to the annular and central electrodes.. .
Valencia Technologies Corporation

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula (i); and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Treprostinil derivatives and compositions and uses thereof

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension..
Corsair Pharma, Inc.

System and relieving hypertension

A system and method for relieving hypertension includes an energy wave generator set an energy wave's frequency control mode for controlling and generating energy waves with correspond energy densities in multiple energy wave generation periods to effect on a body with hypertension, so as to relieve hypertension by the specific energy wave.. .

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue, in embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms..
Neurotronic, Inc.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula i (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Treatment of right ventricular dysfunction due to pressure overload

A method is disclosed for inducing right ventricular (rv) adaptive remodeling in a patient suffering from pulmonary hypertension (ph) due to pressure overload comprising administering a therapeutically effective amount of a carditrophin-1 polypeptide, recombinant protein or a polynucleotide encoding ct-1 polypeptide or full-length protein.. .
Ottawa Hospital Research Institute

Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension

The present invention provides anti-activin a antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (pah).. .
Regeneron Pharmaceuticals, Inc.

Compositions and methods for preventing or treating pulmonary hypertension

The present invention provides a method of treating and/or preventing pulmonary hypertension in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bioactive peptide preparation derived from at least one botanical source.. .
The Regents Of The University Of Colorado, A Body Corporate

Pharmaceutical compositions for combination therapy

The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e.g., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (pbc), primary sclerosing cholangitis (psc), portal hypertension, bile acid diarrhea, nafld (nonalcoholic fatty liver disease), nash (non-alcohol-induced steatohepatitis), and other chronic liver diseases.
Intercept Pharmaceuticals, Inc.

Methods and agents for treating disease

The present invention provides compounds having the general structural formula (i) [formula should be inserted here] and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.. .
Angion Biomedica Corp.

1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase

Compounds of formula i and a method for their preparation are described, where r1, r2 and r3 are the same or different and signify hydrogens, halogens, alkyl, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; r4 signifies -alkyl-aryl or alkyl heteroaryl; x signifies ch2, oxygen atom or sulphur atom; n is 2 or 3; including the individual (r)- and (s)-enantiomers or mixtures of enantiomers thereof; and including pharmaceutically acceptable salts and esters thereof. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure..
Bial - Portela & Ca, S.a.

1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

For use in treating pulmonary arterial hypertension and associated conditions, where r1, r2 and r3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; r4 signifies hydrogen, alkyl, -alkylaryl or -alkylheteroaryl; x signifies ch2, oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that when n is 1, x is not ch2; and the individual (r)- and (s)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof.. .

Composition of chinese medicines and application method thereof for externally treatment for hypertension

A composition of chinese medicines for externally treatment for hypertension includes following herbs: evodia rutaecarpa, chuanxiong, sunflower disc, rhizoma typhonii, angelica, prunella vulgaris, taxillus chinenesis, herba siegesbeckiae, chamomile, astragalus, uncaria rhynchophylla, asarum, and burdock, wherein a weight ratio of the composition is: evodia rutaecarpa 40-50, chuanxiong 30-40, sunflower disc 20-30, rhizoma typhonii 20-25, angelica 20-25, prunella vulgaris 20-30, herba siegesbeckiae 20-30, taxillus chinenesis 20-30, chamomile 20-25, astragalus 20-25, uncaria rhynchophylla 20-30, asarum 20-25, and burdock 20-25.. .

Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (ppar) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension.
Ardelyx, Inc

Cardiovascular disease treatment and prevention

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both.
Transdermal Biotechnology, Inc.

Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata

The present invention relates to a blood pressure lowering composition which contains as an active ingredient exopolysaccharide produced by means of ceriporia lacerata, a ceriporia lacerata mycelium culture medium comprising same, or dry powder or an extract of same. The composition can be used as an antihypertensive for preventing or treating hypertension or cerebral apoplexy or as a functional health food having antihypertensive effect..
Fugenbiopharma Co., Ltd.

Extracellular vesicles with enhanced potency

Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.. .
United Therapeutics Corporation

Pharmacotherapy for preventing or treating glaucoma

A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α2 agonist for preventing or treating glaucoma..
Kowa Company, Ltd.

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor

The invention is related to metabolically stable apelin analogs and their use for the prevention or the treatment of diseases mediated by the apelin receptor in particular of cardiovascular disease (heart failure, hypertension, pulmonary hypertension, kidney failure) and inappropriate vasopressin secretions (siadh).. .
Universite De Strasbourg

Angiotensin-1-receptor antagonists

In which aa1, aa4, aa5, and aa8 are defined in the specification. The compounds of formula (i) can be used to treat hypertension (e.g., hypertension induced by pregnancy), preeclampsia, or a renal disease induced by pregnancy..

5-ht2b antagonists

And related methods for treating a person having a disorder characterized by undesirable 5-ht2b receptor signaling, such as migraine, irritable bowel syndrome (ibs), pulmonary arterial hypertension (pah), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (gi) tract disorders.. .

Hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., syndrome x), thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Compositions and use of a-type procyanidins

The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing a-type procyanidins, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent no-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease and/or vascular circulation disorders, prevent or reduce the risk of heart attack, stroke, congestive heart failure and/or kidney failure, or to improve blood flow, for example renal blood flow. The composition may optionally contain an additional no modulating agent and/or a cardiovascular-protective or therapeutic agent, or may be administered in combination with such an agent..
Mars, Incorporated

System and continuous monitoring of blood pressure

The present invention describes a system and method for continuous monitoring of central (aortic) and peripheral blood pressure. The system includes a fully mobile, non-invasive, continuous blood pressure monitoring system that includes one or more biostrip devices affixed on a user, coupled with an application running on a computing device, which is further connected to a web server in the cloud.
Fourth Frontier Technologies Pvt. Ltd.

Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof

Pyridinecarboxamide derivatives, preparation methods, and a pharmaceutical uses thereof are provided. In particular, pyridinecarboxamide derivatives represented by general formula (i), wherein the substituents of the formula (i) are defined in the specification are provided.
Shanghai Hengrui Pharmaceutical Co., Ltd.

Preservative-free treprostinil formulations and methods and devices for use with same

This invention provides for a unit dosage form of treprostinil at a dosage of between 0.1 mg/ml and 25 mg/ml in a sterile fluid composition formulated for subcutaneous or intravenous injection, which composition does not comprise an antimicrobial preservative. Selectively activatable patch-pump assemblies comprising a sealed prefilled drug-reservoir containing the unit dosage form is described as are methods for reducing pain at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof, and methods of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof.
Steadymed Ltd.

Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (ppar) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension.
Ardelyx, Inc.

Systems and methods for making encapsulated hourglass shaped stents

Systems and methods for the manufacture of an hourglass shaped stent-graft assembly comprising an hourglass shaped stent, graft layers, and an assembly mandrel having an hourglass shaped mandrel portion. Hourglass shaped stent may have superelastic and self-expanding properties.
V-wave Ltd.

Anti-acth antibodies and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.

Organic compositions to treat beta-enac-related diseases

The present disclosure relates to rnai agents useful in methods of treating beta-enac-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (pha1), liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a rnai agent to beta-enac.. .
Arrowhead Pharmaceuticals, Inc.

Method of treating hypertension

The present invention relates to methods and composition for treatment of hypertension. Particularly the present invention provides a method of treating hypertension comprising orally administering once a day to a human patient in need thereof the compound valsartan in an extended release dosage form, wherein said extended release valsartan dosage form reduces mean systolic and diastolic blood pressure in a patient during a time period of about 20 hours to about 24 hours after administration to a greater extent than an immediate release formulation of valsartan..
Rubicon Research Private Limited

Methods of manufacturing treprostinil and treprostinil derivative prodrugs

Methods for making prodrugs of trepreostinil and treprostinil derivatives are provided. Specifically, methods are provided herein for producing prostacyclin compounds comprising treprostinil covalently linked to a linear c5-c18 alkyl, branched c5-c18 alkyl, linear c2-c18 alkenyl, branched c3-c18 alkenyl, aryl, aryl-c1-c18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide).
Insmed Incorporated

Composition

The present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) streptococcus thermophilus cbs 139100 and lactobacillus delbrueckii subsp.
Optibiotix Limited

Short acting phenylalkylamine calcium channel blockers and uses thereof

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods..

Short acting phenylalkylamine calcium channel blockers and uses thereof

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods..

Short acting phenylalkylamine calcium channel blockers and uses thereof

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods..

. .

Methods for treatment of disease using galvanic vestibular stimulation

Methods are provided for treating diseases by altering body mass composition in a human subject through application of galvanic vestibular stimulation (gvs) using electrodes placed in electrical contact with the subject's scalp at a location corresponding to each of the subject's left and right vestibular systems. The methods may be used to treat obesity-related diseases such as diabetes, hypertension, type 2 diabetes mellitus and osteoporosis.
The Regents Of The University Of California

Binding proteins specific for lox1 and uses thereof

This disclosure provides lox1 (lox1) binding proteins such as anti-lox1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the lox1-binding proteins provided herein, inhibit, or antagonize lox1 activity.
Medimmune Limited

An inhalable rapamycin formulation for the treatment of pulmonary hypertension

The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (pah) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.. .
Lam Therapeutics, Inc.

Devices, systems, and methods to treat hypertension

Devices, systems, and methods to treat hypertension. In at least one embodiment of a method of the present disclosure, the method comprises the step of obtaining data indicative of a renal artery of a patient with hypertension; and if the data indicates that the renal artery is stiff, relatively stiff, noncompliant, or relatively noncompliant, the method further comprises the step of performing a renal ablation procedure on the renal artery to treat the hypertension..

Cardiac troponin i detection during pregnancy for cardiovascular disease identification and risk assessment

The present invention provides systems and methods for determining and reporting the cardiac troponin i (ctni) concentration in a sample from a pregnant woman (in the first, second, or third trimester) by determining whether the sample (ctni) concentration is higher than a 99th percentile ctni concentration from a corresponding first, second, or third trimester uncomplicated pregnancy control group, thereby determining if the pregnant woman has or is at risk of developing cardiovascular disease, such as gestational hypertension.. .

Sphingosine kinase inhibitors

Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both.

Treprostinil derivatives and compositions and uses thereof

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension..

Rho associated kinase (rock) inhibitors and their use in treating disease

The present disclosure describes peptide inhibitors of rho-associtated-kinase (rock) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the united states. An inhibitory polypeptide blocks rock1 activity in the presence of 1 mm atp.

Cardiosphere-derived cells (cdcs) as therapeutic agents for pulmonary hypertension

Described herein are compositions and techniques for treatment of disease and conditions such as pulmonary arterial hypertension (pah). Unlike palliative or preventive measures that do not address the abnormal vasculature causing onset of right ventricular compensation the use of stem cell-based therapy can directly impact the microvascular pathology in pah, thereby reversing the course of the disease..

Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

The present application provides methods for treating cardiovascular conditions. The methods can include administering a transient receptor potential vanilloid 1 (trpv1) receptor agonist to an epidural space.

Improved sugar-depleted fruit or vegetable juice and juice-retaining fruit or vegetable derived matter, methods of producing the same and the use thereof to maintain health and to treat and prevent medical ailments

The present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l ca2+, (iii) at least about 1 g/l k+, and (iii) at least about 0.1 g/l mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g.

Mapping sympathetic nerve distribution for renal ablation and catheters for same

This invention provides methods for mapping and ablating renal nerves to treat disease caused by systemic renal nerve hyperactivity, e.g. Hypertension, heart failure, renal failure and diabetes.

Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof

The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection..
University Of Texas Board Of Regents

Nitric oxide donating carnosine compounds

The present invention relates to nitric oxide donor carnosine derivatives having a great efficacy in reducing elevated intraocular pressure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.. .
Nicox Science Ireland

Methods and apparatus to stimulate the heart

A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction.
Backbeat Medical, Inc.

Therapeutic vibration system

A therapeutic vibrational system for treating such conditions as hypertension may have a plurality of vibrating patches; each including a vibrating motor with an adhesive for application to a person's skin permitting the plurality of vibrating patches to be placed in two or more locations on the person's skin, as well as a controller with a user interface and configured to provide control instructions to the plurality of vibrating patches.. .
Sonusmed, Incorporated

Method of treating hypertension

A method of treating hypertension can include administering to a patient in need thereof a therapeutically effective amount of an extract of matricaria chamomilla l. The extract can be administered orally to the patient in an amount of about 100 mg/kg to about 200 mg/kg..
King Saud University

Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor modulator (serm) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes.
Endorecherche, Inc.

Small molecule therapies for pulmonary hypertension

The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.. .
Creighton University

Method for determining risk of pre-eclampsia

The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia.
Wallac Oy

Therapeutic cd47 antibodies

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, cd47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47. Also provided are combinations of any of the foregoing.
Tioma Therapeutics, Inc.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula i and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Use of nitrite salts for the treatment of cardiovascular conditions

It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension.
Wake Forest University

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula i and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula i: (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula i and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Circulating pulmonary hypertension biomarker

Methods and kits for determining, predicting, or diagnosing pulmonary artery hypertension (pah) and for determining the efficacy of pah therapy using biomarkers are provided.. .
The Johns Hopkins University

Tripeptide compound, preparation method therefor, and application thereof

Provided are a tripeptide compound, a preparation method therefor, and an application thereof. The structure of the related compound is represented by formula (i).
Northwest University

Negative hydrogen ion intellegrnt filtration system for curing cancer, cardiovascular disease, diabetes, hypertension, nephrotic syndrome, gout, dysautonomia and atopic dermatitis

A negative hydrogen ion intelligent filtration system includes a housing; a filtering mechanism disposed in the housing and comprising a first filter, a second filter connected to the first filter, a third filter connected to second filter, a fourth filter connected to the third filter, a fifth filter connected to the fourth filter, a sixth filter connected to the fifth filter, a seventh filter connected to the sixth filter, an eighth filter connected to the seventh filter, a ninth filter connected to the eighth filter, a tenth filter connected to the ninth filter, a eleventh filter connected to the tenth filter and a twelfth filter connected to the eleventh filter; an inflow port connected to the first filter and extending out of the housing; an outflow port connected to the twelfth filter and extending out of the housing; and a flow rate control mechanism disposed in the housing, located between the first filter and the inflow port and connecting the first filter and the inflow port.. .
Mega Sun Biomedical Corp.

Enalapril formulations

Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction..
Silvergate Pharmaceuticals, Inc.

Renal neuromodulation for treatment of patients

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve.
Medtronic Ardian Luxembourg S.a.r.l.

Methods of inhibiting pathological angiogenesis with doppel-targeting molecules

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (pah), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described..
Pharosgen

Sustained timolol maleate delivery from liposomes for glaucoma therapy and occular hypertension

Various embodiments relate to the field of liposomal formulations for drug delivery, in particular, liposomal formulations for ocular drug delivery. More specifically, various embodiments relate to sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension..
Nanyang Technological University

Methods for therapeutic renal neuromodulation

Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.

Therapeutic use of peptide inhibitors of nadph oxidase; aerosolization as a delivery mechanism

A method is provided for treatment of a condition mediated by nox2 in a patient. The method comprises administering to the patient by inhalation a polypeptide as described herein, able to inhibit superoxide production by nox2.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

G protein-coupled receptor kinase 2 inhibitors and methods for use of the same

Disclosed herein are novel grk2 inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of formula (i) and pharmaceutically acceptable salt thereof: wherein the substituents are as described..
The Regents Of The University Of Michigan

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals

The present invention relates to combination of one or more sglt2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more disorders selected from equine metabolic syndrome (ems), equine pituitary pars intermedia dysfunction (ppid), also known as equine cushing's syndrome, laminitis, vascular dysfunction, hypertension, hepatic lipidosis, hyperadreeocorticism, glucose intolerance, insulin resistance, hyperinsulinaemia, hirsutism, hyperhidrosis. Polyuria, polydipsia, chronic infections, abnormal fat distribution, muscle wasting, abnormal weight loss and/or loss of appetite..
Boehringer Ingelheim Vetmedica Gmbh

Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension

Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed.
Novartis Ag

Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..
Los Angeles Biomedical Research Institute At Harbor- Ucla Medical Center

Oral end tidal carbon dioxide probe for diagnosing pulmonary arterial hypertension

This disclosure concerns improved capabilities for evaluating pulmonary arterial hypertension (pah). A system and method of evaluating pah in a subject may include measuring end tidal partial pressure of exhaled carbon dioxide in the subject, wherein the measurement is made orally using described systems or devices.
Vanderbilt University

Cyclic polypeptides for the treatment of heart failure

Or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein x1, x3, x4, x7, x8, x9, x10, x11, x12 and x13 are defined herein. The polypeptides are agonist of the apj receptor.

Methods for therapeutic renal neuromodulation

Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.

Method of treating copd with artificial arterio-venous fistula and flow mediating systems

A method for treatment of copd, hypertension, and left ventricular hypertrophy, and chronic hypoxia including creation of an artificial arterio-venous fistula and installation of a flow mediating device proximate the fistula. The flow mediating device is operated to limit flow as medically indicated to provide the optimum amount of bypass flow..
Rox Medical, Inc.

Elevated intracranial pressure treatment

Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (icp) in a subject. Methods of reducing elevated icp in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject.
The University Of Birmingham

Methods and compositions for prevention and treatment of cardiac hypertrophy

Methods are provided of treating cardiac hypertrophy in a mammalian subject comprising administering to the subject an anti-hypertrophic effective amount of an ion channel tr-pv1 inhibitor. The methods include treatment of a symptom of cardiac hypertrophy in the subject comprises cardiac remodeling, cardiac fibrosis, apoptosis, hypertension, or heart failure.
University Of Hawaii

Electronic phenotyping technique for diagnosing chronic kidney disease

An example method of diagnosing chronic kidney disease (ckd) includes obtaining an electronic medical record for a patient having medical data. The medical data includes an indication if the patient had been previously diagnosed with ckd, an indication if the patient had previously undergone a kidney transplant, an indication if the patient had previously undergone a renal dialysis procedure, an indication if the patient had previously been diagnosed with another type of kidney disease, one or more glomerular filtration rate (gfr) measurements associated with the patient, an indication if the patient has type 2 diabetes, and/or an indication if the patient has hypertension.
Icahn School Of Medicine At Mount Sinai

Identification of cattle at risk of high altitude pulmonary hypertension

Provided herein are methods and compositions for determining the susceptibility of cattle to high altitude pulmonary hypertension. Also provide are kits and reagents for performing such methods..
Colorado State University Research Foundation

Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases

The present invention relates to methods, kits and compositions to treat hypertension in a subject comprising inhibiting activity or expression of at least one microrna.. .
The Brigham And Women's Hospital, Inc.

Difluoropyrrolidines as orexin receptor modulators

The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.. .
Eolas Therapeutics, Inc.

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

System and optogenetic therapy

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations.
Circuit Therapeutics, Inc.

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

Methods for predicting risk of developing hypertension

Methods using biomarkers, e.g., serum levels of st2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.. .
Critical Care Diagnostics, Inc.

Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.. .
The Scripps Research Institute

Dry powder inhaler

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation..
Mannkind Corporation

Sildenafil sublingual spray formulations

The invention is directed to sublingual spray formulations containing sildenafil. The invention is further directed to methods of treating male sexual dysfunction or pulmonary arterial hypertension by administering sublingual spray formulations containing sildenafil to patients in need of such treatments..
Insys Development Company, Inc.

Lisinopril formulations

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction..
Silvergate Pharmaceuticals, Inc.

Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile..
Recro Gainesville Llc

Process for the preparation of kinase inhibitors and intermediates thereof

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. Eye disease, such as glaucoma and ocular hypertension, in a subject..
Aerie Pharmaceuticals, Inc.

Systems and methods for treating pulmonary hypertension

A system for treating heart disease, such as pulmonary hypertension or right heart failure, including an implantable component and external components for monitoring the implantable component is provided. The implantable component may include a compliant member, e.g., balloon, coupled to a reservoir via a conduit.
Aria Cv, Inc.

Methods and compositions relating to treatment of pulmonary arterial hypertension

The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. Pulmonary arterial hypertension, relating to inhibition of tgfβ1, tgfβ3, and/or gdf-15..
The Brigham And Women's Hospital, Inc.

Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof

Compositions and preparation method thereof, said compositions comprise an extract from a mixture comprising cyclocarya paliurus leaves and one or more herbs selected from the group consisting of mori cortex, dendrobii caulis and citri reticulatae pericarpium, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.. .
Infinitus (china) Company Ltd

Sustained release delivery of active agents to treat glaucoma and ocular hypertension

A method of decreasing intraocular pressure (iop) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent..
Mati Therapeutics Inc.

Water dispersible mini-tablets comprising enalapril for treatment of hypertension in a pediatric population and preparation thereof

The present invention relates to water dispersible mini-tablets of enalapril or a pharmaceutically acceptable salt thereof for use in the treatment of hypertension in a pediatric formulation. The pediatric formulation is defined as 0 to 18 years of age.
Pharmathen S.a.

Composition, device, and detecting olmesartan and improving compliance in treating hypertension

This disclosure provides compositions, including antibodies or fragments or derivatives thereof, and related devices and methods effective for detecting and quantifying olmesartan in a sample. The compositions, devices, and methods can be applied to improve the effectiveness of hypertension therapy by monitoring a subject's compliance by determining one or more pharmacokinetic parameters of the subject with a point-of-care device after antihypertensive drug administration.
Autotelic Llc

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula i and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Agonists of the apelin receptor and methods of use thereof

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Sanford-burnham Medical Research Institute

Conversion of nitrogen dioxide (no2) to nitric oxide (no)

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid..
Geno Llc

Cardiovascular disease treatment and prevention

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both.
Transdermal Biotechnology, Inc.

Toa Eiyo Ltd.

. .

Pyridine derivative

Provided is a pyridine derivative represented by formula (i), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with urat1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and lesch-nyhan syndrome.. .
Teijin Pharma Limited

Angiotensinogen (agt) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the angiotensinogen (agt) gene, and methods of using such rnai agents to inhibit expression of agt and methods of treating subjects having an agt-associated disorder, e.g., hypertension.. .
Alnylam Pharmaceuticals, Inc.

Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Cientificas

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Handheld physiological sensor

A handheld device measures all vital signs and some hemodynamic parameters from the human body and transmits measured information wirelessly to a web-based system, where the information can be analyzed by a clinician to help diagnose a patient. The system utilizes our discovery that bio-impedance signals used to determine vital signs and hemodynamic parameters can be measured over a conduction pathway extending from the patient's wrist to a location on their thoracic cavity, e.g.
Tosense, Inc.

Methods of inhibiting pathological angiogenesis with doppel-targeting molecules

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (pah), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described..
Pharsogen

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache, and pain control, asthma, angina, hypertension, depression, cold, flue and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
Merck Patentgesellschaft

Exo-s-mecamylamine formulation and use in treatment

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg.
University Of South Florida

Enalapril compositions

Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction..
University Of Kansas

Improved therapeutic regimen for hypertension

The invention relates to improved methods, devices, and kits for identifying and implementing an appropriate treatment regimen for subjects suffering from hypertension.. .
Geneticure Llc

Compositions and methods of preventing erythropoietin associated hypertension

The invention also provides a method of reducing hypertension in a mammal receiving epo, and pharmaceutical compositions containing a soluble epo-bp and/or a recognition protein that binds epo receptor on an extracellular soluble portion of the epo receptor.. .

Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof

Compositions and preparation method thereof, said compositions comprise herb extract from a mixture comprising cyclocarya paliurus leaf and one or two herbs selected from the group consisting of puerariae lobatae radix and polygonati odorati rhizoma, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.. .
Infinitus (china) Company Ltd

Tea composition comprising cyclocarya paliurus and preparation method and uses thereof

Compositions and preparation method thereof, said compositions comprise cyclocarya paliurus leaf and one or more herbs selected from the group consisting of green tea, mori folium, siraitiae fructus, broadleaf holly leaf and polygonati odorati rhizoma, and their preparation method. Said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia..
Infinitus (china) Company Ltd

Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population

The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age.
Pharmathen S.a.

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild cognitive impairment (mci), alzheimer's disease, lupus, huntington's disease, parkinson's, dyskinesia, adhd, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (mdd), drug dependence, tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension. The present invention further provides a d1 agonist with reduced d1r desensitization, a d1 agonist with a reduced β-arrestin recruitment activity relative to dopamine, a d1 agonist interacting significantly with the ser188 but not significantly with the ser202 of a d1r when binding to the d1r, a d1 agonist interacting less strongly the asp103 and interacting less strongly with the ser198 of a d1r when binding to the d1r, and their uses..

Prevention and treatment of cardiovascular diseases using transdermal nitric oxide delivery

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide.
Anthura B.v.

Method of treating hypertension

Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of anagrelide or derivative thereof.
Cipla Limited

Allisartan isoproxil polymorph, its preparation method and pharmaceutical

Disclosed are polymorph of allisartan isoproxil and a pharmaceutical composition thereof. The polymorph is non-electrostatic, highly flowable and highly stable, and can be used for treating hypertension and complications thereof..
Shenzhen Salubris Pharmaceuticals Co., Ltd

Pyrazine derivatives

Provided is a novel pyrazine derivative represented by the following formula (i) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which urat1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, lesch-nyhan syndrome, and the like.. .
Teijin Pharma Limited

Methods and compositions for treating diseases and conditions

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea.
Afferent Pharmaceuticals Inc.

Phoenixin peptides

Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of camp, and treatment of disorders related to camp or ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.. .

Oxytocin improves treatment of obstructive sleep apnea

The present disclosure provides methods for treating obstructive sleep apnea (osa) and osa induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: osa or osa induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin.

Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits gdf15 activity..
Aveo Pharmaceuticals, Inc.

Process for the preparation of kinase inhibitors and intermediates thereof

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. Eye disease, such as glaucoma and ocular hypertension, in a subject..
Aerie Pharmaceuticals, Inc.

Method for treating a pulmonary hypertension condition

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (pah) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years. .
Gilead Sciences, Inc.

Formulations of l-ornithine phenylacetate

Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders..
Ocera Therapeutics, Inc.

Devices and methods for control of blood pressure

Apparatus and methods are described, including identifying a subject as suffering from hypertension. In response to the identifying (a) a radius of curvature of a first set of at least three regions of an arterial wall of the subject is increased at a given longitudinal location, while (b) allowing the first set of regions of the arterial wall to pulsate.
Vascular Dynamics, Inc.

Methods of detecting and treating pulmonary hypertension

The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques.
Rensselaer Center For Translational Research, Inc.

Method for treating secondary pulmonary hypertension

Method for ameliorating secondary pulmonary hypertension in a patient including determining a pulmonary vascular resistance (pvr) of the patient suffering from secondary pulmonary hypertension; assessing a change in the pvr in response to a selection treatment; and treating the patient with a pulmonary artery manipulation device to provide pulmonary artery denervation if the patient is determined to suffer from fixed ph, thereby ameliorating the secondary pulmonary hypertension of the patient.. .
Sonivie Ltd.

Takeda Pharmaceutical Company Limited

. .

Lisinopril formulations

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction..
Silvergate Pharmaceuticals, Inc.

Magnesium compositions and uses thereof for neurological disorders

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
Neurocentria, Inc.

Hypotensive lipid and timolol compositions and methods of using same

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component.
Allergan, Inc.

Methods and materials for treating hypertension

This document provides methods and materials involved in treating hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension). For example, methods and materials involved in administering one or more sympatholytic agents to a patient to identify the patient as having an elevated baseline level of sympathetic nerve activity and performing renal denervation on the identified patient to reduce a symptom of hypertension (e.g., resistant hypertension) are provided..
Mayo Foundation For Medical Education And Research

Methods, systems and devices for treating hypertension

Provided is a method of treating arterial hypertension in a patient. The method comprises selecting a patient suffering from arterial hypertension and creating a flow pathway between a first vascular location and a second vascular location.
Rox Medical, Inc.

Magnesium compositions and uses thereof for neurological disorders

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
Neurocentria, Inc.

Substituted prolines / piperidines as orexin receptor antagonists

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.

Urea compounds and their use as enzyme inhibitors

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

Treatment of the complications of chronic liver disease with caspase inhibitors

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein..
Conatus Pharmaceuticals, Inc.

Salt-free miso production method, salt-free miso, hepatic function improvement agent, and hypertension improvement agent

Provided are: a production method for salt-free miso, in which steamed soy beans and koji are pressurized, heated, and fermented; salt-free miso obtained by said production method; and a hepatic function improvement agent and a hypertension improvement agent that contain said salt-free miso as an effective component thereof.. .
Masuyamiso Co., Ltd.

Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids.
Complexa, Inc.

Palatin Technologies, Inc.

. .

Method of testing for pulmonary hypertension

A primary object of the present invention is to provide a method for conveniently and accurately testing for pulmonary hypertension. To achieve this object, the present invention provides a method for testing for pulmonary hypertension using as an indicator the concentration of selenoprotein p protein in a sample derived from a subject..
Tohoku University

Pulmonary hypertension biomarker

Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension.
Novartis Ag

Carboxamide inhibitors

The compounds of formula i demonstrate properties as smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.. .

Carboxamide inhibitors

The compounds of formula i demonstrate properties as smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.. .

Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet.
Md Healthcare Inc.

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Provided herein are multiple solid forms of a defined α,{acute over (ω)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof.
Allergan, Inc.

Treprostinil derivative compounds and methods of using same

Compounds represented by formulae i, ii, iii, and iv including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (ph) or pulmonary arterial hypertension (pah).
Corsair Pharma Inc.

Therapy for complications of diabetes

A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg

Methods of treating intraocular pressure with activators of tie-2

Disclosed herein are compounds effective for activation of tie-2 and inhibition of hptp-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma..
Aerpio Therapeutics, Inc.

Mif inhibitors for the acute or chronic treatment of pulmonary hypertension

The present invention relates to the use of compounds of general formula i and pharmaceutically acceptable enantiomers, salts or solvates thereof, for treating pulmonary hypertension in a subject.. .
UniversitÉ Paris-sud 11

Diabetes and hypertension screening by assessment of arterial stiffness and autonomic function

The present invention provides methods and apparatuses to assess vascular stiffness of a subject, and to assess diabetes or hypertension from the assessment of vascular stiffness. Example embodiments comprise determining arrival at a peripheral site of a blood pressure wave as a function of time relative to the cardiac cycle of the subject at a plurality of measurement conditions, wherein at least two of the conditions are characterized by at least one of: (a) different central transmural pressure, (b) different peripheral transmural pressure; assessing vascular stiffness from the determinations at the plurality of measurement conditions..
Medici Technologies, Llc

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Use of modified vasoactive intestinal peptides in the treatment of hypertension

The present invention is based on the discovery that a vip having a binding preference for vpac2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided..
Phasebio Pharmaceuticals, Inc.

Serca2 therapeutic compositions and methods of use

The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (aav)-serca2 composition to a subject in need thereof.. .
Icahn School Of Medicine At Mount Sinai

Ablation targeting nerves in or near the inferior vena cava and/or abdominal aorta for treatment of hypertension

A method for the treatment of a patient for the purpose of lowering blood pressure and/or treating other medical conditions such as cardiac arrhythmias. A catheter having an ablation element is placed inside the body of a patient and is directed to a targeted location either on in the abdominal aorta where the right or left renal arteries branch from the aorta at or near the superior junction or ostia or on the inside of the inferior vena cava near the junction with the right renal vein or in the left renal vein at a position spatially near where the left renal artery branches from the abdominal aorta.
Biosense Webster (israel), Ltd.

Methods for therapeutic renal neuromodulation

Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.

Methods and materials for treating elevated sympathetic nerve activity conditions

This document provides methods and materials involved in treating hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease). For example, methods and materials involved in administering one or more sympatholytic agents to a patient to identify the patient as having an elevated baseline level of sympathetic nerve activity and treating the identified patient with a sympatholytic therapy to reduce the symptoms of hypertension (e.g., resistant hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease) are provided..
Mayo Foundation For Medical Education And Research

Japan Tobacco Inc.

. .

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

Substituted pyridazines as prostacyclin receptor modulators

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Method of reducing renal hypertension and computer-readable medium

A method of reducing renal hypertension applied for electrically stimulating a target zone of an organism having a symptom of renal hypertension by using an electronic stimulation device. The electronic stimulation device comprises at least one electronic stimulation unit.
Gimer Medical Co., Ltd.

Prostamide-containing intraocular implants and methods of use thereof

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle.
Allergan, Inc.

Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions

Methods and compounds for research and treatment of portal hypertension. The use of racemic or non-racemic mixtures of furopyridine isomers to stimulate enos function in sinusoidal endothelial cells and to increase no production in both normal sinusoidal endothelial cells and injured endothelial cells..

Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

The disclosed subject matter provides certain n-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition.
The Johns Hopkins University

Prostacyclin compounds, compositions and methods of use thereof

Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear c5-c18 alkyl, branched c5-c18 alkyl, linear c2-c18 alkenyl, branched c3-c18 alkenyl, aryl, aryl-c1-c18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described.
Insmed Incorporated

Novel formulations and methods

Nanoparticles comprising vip and their use in treating, e.g., pulmonary hypertension. Such nanoparticles provide improved delivery of vip and allow for acute treatment and optionally for sustained release of vip in a patient..
Avant Garde Therapeutics And Technologies, Llc

Intraocular pressure modification

Assemblies and methods for modifying an intraocular pressure of a patient's one or both eyes are disclosed. The assemblies and methods can be used to treat, inhibit, or prevent ocular conditions such as glaucoma, high intraocular pressure, optic disc edema, idiopathic intracranial hypertension, zero-gravity induced papilledema, and other optic pressure related conditions.
Dr. John Berdahl

Wellstat Therapeutics Corporation

. .

Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaecutical use

The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (ndga) compounds and butane bridge modified tetra-o-substituted ndga compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as hiv infection, hpv infection, or hsv infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.. .
Erimos Pharmaceuticals Llc

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Method of treating pulmonary arterial hypertension

The present invention is concerned with the treatment of pulmonary arterial hypertension (pah) by administering paliperidone. The instant invention further relates to use of a pharmaceutical composition comprising paliperidone, for the treatment of pah..
Cipla (uk) Limited

Device and treatment of retinal detachment and other maladies of the eye

The present invention includes a device and method for treatment of retinal detachment, ocular hypertension and glaucoma, and increasing an amplitude of accommodation. The device includes a tapered, mesh tube that within a sclera, expands to deform the sclera, and when placed within the posterior sclera for the treatment of a retinal tear, the device expands deforming the sclera so that the retinal pigment epithelium comes in contact with the retinal tear to seal the tear.

5-ht2b antagonists

And related methods for treating a person having a disorder characterized by undesirable 5-ht2b receptor signaling, such as migraine, irritable bowel syndrome (ibs), pulmonary arterial hypertension (pah), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (gi) tract disorders.. .

Dietary compositions for reducing blood glucose levels and for weight management

The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.

Carrier status of annexin a5 m2 haplotype and obstetric risks

The present invention relates to determining the carrier status of annexin a5 m2 haplotype of parents (both male and female) prior to and/or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (rpl), infertility, miscarriage, in vitro fertilization (ivf) failure, iui failure, implantation failure, foetal growth restriction (fgr), small for gestational age (sga) newborn, intra-uterine foetal death (iufd), gestational hypertension (gh), pre-eclampsia (pe) and/or venous thromboembolism (vte). Once m2 carrier status is determined, methods of intervention, including administration of low molecular weight heparin (lmwh) and/or other anti-coagulants can be administered either prior to and/or after pregnancy.
Ihg Pharmaco Limited

Compositions and methods of inhibiting histone deacetylases

The present invention provides compositions and methods for treating pulmonary hypertension. In one aspect, a method is included for increasing myocyte enhancer factor 2 (mef2) activity in an endothelial cell comprising exposing the cell to a class iia histone deacetylase inhibitor.
Yale University

Medical imaging

The present invention relates to methods for assessing or obtaining an indication of vascular pressure associated with organs or visceral tissues of the body by using mri imaging methods. The invention particularly relates to methods for assessing or obtaining an indication of portal hypertension using magnetic resonance t1, or t1 and t2* relaxometry, and t1, t2 and/or t2* mapping of the liver or spleen..
Oxford University Innovation Limited

Benzimidazole derivatives and preparation process and pharmaceutical uses thereof

The invention belongs to the technical field of pharmaceutical chemistry, and particularly pertains to benzimidazole derivatives, and preparation process and pharmaceutical uses thereof. Benzimidazole derivatives include ligustrazine and no donor derivatives.
Wuhan Qr Pharmaceuticals Co., Ltd

Potassium-binding agents for treating hypertension and hyperkalemia

The present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.
Relypsa, Inc.

Drug therapy for preventing or treating glaucoma

There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma..
Kowa Co., Ltd.

Volant Holdings Gmbh

. .

Administration of iloprost as aerosol bolus

The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy.
Vectura Gmbh

Pharmaceutical administration system for the transdermal application of vardenafil

A pharmaceutical administration system for the transdermal application of at least one active agent includes vardenafil and/or a pharmaceutically acceptable salt thereof as the active agent and a pharmaceutically acceptable carrier providing a solution of the at least one active agent in the administration system. Another active agent may be testosterone.
Lipp Life Sciences Llc

Volant Holdings Gmbh

. .

Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions

Rna interference is provided for inhibition of connexin 43 (cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.. .
Arrowhead Pharmaceuticals, Inc.

Novel cyp-eicosanoid derivatives

The present invention relates to compounds according to general formula (i) which are analogues of epoxymetabolites produced by cytochrome p450 (cyp) enzymes from omega-3 (n-3) polyunsaturated fatty acids (pufas). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for c the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias..
Board Of Regents, The University Of Texas System

Medication and application for treatment of hypertension based on anion and traditional chinese medicine

A medicament for treatment of hypertension based on anion and traditional chinese medicine, containing active ingredients by percentage weight, which are: 9˜30% of scutellaria baicalensis, 3˜9% of radix bupleuri, 3˜12% of uncaria tomentosa (cat's claw), 3˜9% of ginseng, 15˜25% of cynanchum mooreanum hemsl., 3˜9% of cordyceps sinensis (berk.) sacc., 10˜15% of flastem milkvetch seed, 9˜15% of dermatocarpon miniatum(l.)mann. [lichen miniatius l.], 10˜15% of millettia dielsiana, 10˜15% of stem or root of dalbergia hancei benth.

Use of fk506 for the treatment of pulmonary arterial hypertension

A method for reducing pulmonary hypertension in a mammal that employs fk506 is provided. In certain embodiments, the method comprises administering fk506 to a mammal having pulmonary arterial hypertension associated with defective mbpr2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal..
The Board Of Trustees Of The Leland Stanford Junior University

Renal neuromodulation for treatment of patients

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve.
Medtronic Ardian Luxembourg S.a.r.l.

Renal neuromodulation for treatment of patients

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve.
Medtronic Ardian Luxembourg S.a.r.l.